Literature DB >> 20675971

Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.

Marco Tuccori1, Sabrina Montagnani, Arianna Testi, Elisa Ruggiero, Stefania Mantarro, Carla Scollo, Alessandra Pergola, Matteo Fornai, Luca Antonioli, Rocchina Colucci, Tiberio Corona, Corrado Blandizzi.   

Abstract

General consensus exists about the need to avoid drug intake as much as possible during pregnancy due to the lack of thorough evidence about the safety of pharmacologic treatments during gestation for both mothers and fetuses. In this respect, the overall safety profile of selective serotonin reuptake inhibitors (SSRIs) in pregnancy remains unclear. This article reviews current evidence about the safety of each SSRI during pregnancy in order to describe their specific teratogenic potential, with a particular focus on major and cardiovascular malformations, and to verify whether such toxicity can be considered as a class effect. The literature review included controlled studies and meta-analyses (retrieved using PsychINFO, EMBASE, and Medline from January 1966 to May 2010) from which the risk of major and/or cardiovascular malformations associated with a specific SSRI (ie, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and fluvoxamine) could be estimated. Although there is evidence to support the association between birth defects and first-trimester exposure to paroxetine, findings from the studies reviewed suggest a teratogenic potential of the whole SSRI class, consistent with preclinical evidence. These teratogenic effects are mainly in the heart region, and they are often described as septal defects. It may be suggested that the higher frequency of teratogenic effects reported for paroxetine might depend on specific pharmacologic features of this drug compared with other SSRIs, although it is difficult to test this hypothesis. It is noteworthy that current evidence on SSRI teratogenicity stems from studies affected by several methodological weaknesses (ie, lack of investigations using control groups of untreated depressed mothers, confounding by indication, and recall bias). Accordingly, we are not yet able to rule out the possibility that positive associations, as determined in some studies, result from analyses of poor quality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675971     DOI: 10.3810/pgm.2010.07.2175

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

Review 1.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

2.  Serotonergic effects on feeding, but not hypothalamus-pituitary-adrenal secretion, are altered in ovine pregnancy.

Authors:  Melissa Lingis; Elaine Richards; Dana Perrone; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-28       Impact factor: 4.310

3.  A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns.

Authors:  Deidra A Ansah; Benjamin E Reinking; Tarah T Colaizy; Robert D Roghair; Sarah E Haskell
Journal:  Neonatology       Date:  2019-03-05       Impact factor: 4.035

4.  Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.

Authors:  Kari Furu; Helle Kieler; Bengt Haglund; Anders Engeland; Randi Selmer; Olof Stephansson; Unnur Anna Valdimarsdottir; Helga Zoega; Miia Artama; Mika Gissler; Heli Malm; Mette Nørgaard
Journal:  BMJ       Date:  2015-04-17

5.  Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung's disease in newborns - a nationwide cohort study.

Authors:  Sebastian Werngreen Nielsen; Perniller Møller Ljungdalh; Jan Nielsen; Bente Mertz Nørgård; Niels Qvist
Journal:  Orphanet J Rare Dis       Date:  2017-06-20       Impact factor: 4.123

6.  Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births.

Authors:  Shan-Yan Gao; Qi-Jun Wu; Ce Sun; Tie-Ning Zhang; Zi-Qi Shen; Cai-Xia Liu; Ting-Ting Gong; Xin Xu; Chao Ji; Dong-Hui Huang; Qing Chang; Yu-Hong Zhao
Journal:  BMC Med       Date:  2018-11-12       Impact factor: 8.775

7.  Hypersensitivity of Zebrafish htr2b Mutant Embryos to Sertraline Indicates a Role for Serotonin Signaling in Cardiac Development.

Authors:  Mitchell E Kent; Bo Hu; Timothy M Eggleston; Ryan S Squires; Kathy A Zimmerman; Robert M Weiss; Robert D Roghair; Fang Lin; Robert A Cornell; Sarah E Haskell
Journal:  J Cardiovasc Pharmacol       Date:  2022-08-01       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.